Small molecule · Inhibitor of exportin-1 (XPO1/CRM1) (XPO1) · developed by Karyopharm Therapeutics
Eltanexor (KPT-8602) is an orally bioavailable selective inhibitor of nuclear export that binds the cargo-binding site of exportin-1 (XPO1). By blocking XPO1-mediated export, it retains tumor suppressor proteins such as p53 in the nucleus of tumor cells, promoting apoptosis. It is studied in myelodysplastic syndrome, acute myeloid leukemia, multiple myeloma and colorectal and prostate cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02649790 | Phase 1/2 | Relapsed/Refractory Multiple Myeloma (RRMM) | Completed | KPTI |
| NCT06399640 | Phase 1 | Relapsed Myelodysplastic Syndrome | Recruiting | KPTI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRelapsed Myelodysplastic SyndromeAcute Myeloid Leukemia (AML)Higher-Risk Myelodysplastic Syndrome (HR-MDS)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Colorectal Cancer (mCRC)Newly Diagnosed Intermediate/High-Risk MDSRelapsed/Refractory Multiple Myeloma (RRMM)
Updated Oct 18, 2026. Something wrong or missing? Report it on the KPTI page.
See KPTI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KPTI catalysts and pipeline →